急性髓系白血病患者血浆中血管内皮生长因子水平及其临床意义

为探讨血管内皮生长因子 (VEGF)在成人急性髓系白血病 (AML)发生发展中的作用 ,采用ELISA方法研究AML病人血浆中VEGF的表达。结果难治性和非难治性AML病人血浆中VEGF浓度分别为 5 5 8.90pg/ml和 392 .5 4 pg/ml,均高于正常人 (5 7 2 7pg/ml)和AML骨髓移植后病人(77 31pg/ml) ,除正常人与AML骨髓移植后病人比较无统计学差异外 ,其他两者之间比较均有显著性差异 (P <0 0 5 )。 18例持续完全缓解中位时间 6个月的AML病人血浆VEGF浓度 (196 14pg/ml)低于非难治性、难治性AML(P值均 <0 0 1) ,而高于AML骨髓移植后病人及正常人血浆中VEGF浓度 (P值均 <0 0 5 )。提示AML病人血浆VEGF水平明显增高 ,在AML的发病机制中可能起一定的作用 ,且可能成为判断AML病人预后的指标之一。

EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN THE PLASMA FROM AML PATIENT AND ITS CLINCAL SIGNIFICANCE

To investigate the role of vascular endothelial growth factor (VEGF) in occurrence and progression of acute myeloid leukemia (AML), enzume linked immunosorbent assay(ELISA) was used for detection of VEGF concentration in plasma from AML patients and normal bone marrow donors.The mean VEGF concentration in the plasma from refractory (558 90pg/ml) and non refractory (392 54pg/ml) AML patients was higher than that from normal donors (57 27pg/ml) and AML patients post Allo BMT (77 31pg/ml).There were significant differences between refractory and non refractory AML group. The baseline VEGF level (196 14pg/ml) of patients in complete remission (CR) after a median follow up of 6 months was significantly lower than that of patients with newly diagnosed or relapsed AML, but significantly higher than that of patients with Allo BMT AML and normal donors. Therefore, abnormal VEGF expession may play an important role in development of AML, and VEGF might be used to evaluate prognosis of AML.